DAWNRAYS PHARMA (02348) · Company profile · Eqvero

DAWNRAYS PHARMA

02348HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1.23 bn CNY	1.06 bn CNY	1.15 bn CNY	1.28 bn CNY	1.17 bn CNY
Cost of revenue	553.31 m CNY	421.63 m CNY	438.77 m CNY	444.59 m CNY	435.64 m CNY
Research and development expense	83.48 m CNY	70.83 m CNY	90.81 m CNY	79.48 m CNY	67.03 m CNY
Selling, general and administrative expense	244.27 m CNY	258.2 m CNY	260.26 m CNY	264.79 m CNY	226.44 m CNY
Operating profit after depreciation	227.42 m CNY	202.05 m CNY	275.99 m CNY	419.1 m CNY	380.76 m CNY
Operating profit before depreciation	347.57 m CNY	308.67 m CNY	359.88 m CNY	485.51 m CNY	434.91 m CNY
EBIT	227.42 m CNY	202.05 m CNY	275.99 m CNY	419.1 m CNY	380.76 m CNY
EBITDA	347.57 m CNY	308.67 m CNY	359.88 m CNY	485.51 m CNY	434.91 m CNY
Interest expense	496 k CNY	3.61 m CNY	989 k CNY	371 k CNY	641 k CNY
Profit before tax	249.61 m CNY	636.95 m CNY	414.06 m CNY	438.41 m CNY	439.32 m CNY
Income tax expense	38.51 m CNY	74.19 m CNY	91.39 m CNY	82.56 m CNY	85.16 m CNY
Income before extraordinary items	213.97 m CNY	564.94 m CNY	326 m CNY	358.06 m CNY	358.18 m CNY
Common dividends	84.1 m CNY	87.71 m CNY	110.71 m CNY	116.15 m CNY	97.96 m CNY
Total dividends	84.1 m CNY	87.71 m CNY	110.71 m CNY	116.15 m CNY	97.96 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.